The White House is preparing to strike at pharmaceutical companies that haven’t bent to Donald Trump’s pricing demands. By Thursday, tariffs could slam drugmakers without agreements—a hardball tactic disguised as national security policy. This isn’t about border economics or trade imbalances in the traditional sense. It’s about forcing an industry to heel, using tariff threats the way a hostage negotiator uses deadlines.
Trump has spent the last year dangling tariff rates between 100% and 200% over the pharmaceutical sector. The stated goal sounds patriotic enough: bring drug manufacturing back to American soil and lower prescription costs for everyday citizens. But the reality playing out in boardrooms and federal offices is messier. Companies like Pfizer and Eli Lilly have already cut deals to escape the hammer. They bought themselves three years of peace by committing to vague promises about domestic production and pricing adjustments. The companies that haven’t signed are now staring down what amounts to economic exile.
This latest move relies on Section 232 of the Trade Expansion Act, a Cold War relic originally designed to protect industries vital to national defense. Steel, aluminum, uranium—those made sense under the law’s original intent. Pharmaceuticals are a stretch, but not without precedent in Trump’s playbook. His first term saw Section 232 weaponized for cars and washing machines. Now it’s prescription drugs. The logic goes that a nation dependent on foreign supply chains for critical medicines is vulnerable during pandemics or geopolitical crises. COVID-19 gave that argument teeth. When India briefly restricted pharmaceutical exports in 2020 and China controlled precursor chemical supplies, Washington panicked quietly.
But invoking national security doesn’t automatically make the policy coherent. According to sources familiar with the administration’s planning, companies without agreements and not actively negotiating will face 100% tariffs on imports. The details remain fluid. There may be carve-outs for specific medications or disease categories, though which ones remains anyone’s guess. The uncertainty itself is a pressure tool. Drugmakers are left scrambling to figure out whether their cancer therapies or diabetes medications might slip through some bureaucratic exemption, or whether they’ll be taxed into irrelevance in the American market.
The pharmaceutical lobby isn’t sitting idle. The Pharmaceutical Research and Manufacturers of America has been in overdrive since Trump’s tariff threats began circulating last year. Their argument hinges on patient access: tariffs will raise costs, not lower them. If a company faces a 100% levy on imports, that expense doesn’t vanish into corporate goodwill. It gets passed to insurers, pharmacy benefit managers, and ultimately patients. The administration’s counter is that companies will simply move production stateside to avoid the tariffs altogether. But building pharmaceutical manufacturing facilities isn’t like opening a new Starbucks. It takes years, billions in capital investment, and regulatory approvals that move at the speed of federal bureaucracy.
There’s also the question of whether this is even legal. Trump’s previous global tariff agenda, rolled out in 2025, was struck down by the Supreme Court in February. The justices found his use of executive authority overreached constitutional limits on trade policy. This new pharmaceutical tariff plan could face similar challenges, especially if companies argue that the national security justification is pretextual. Legal experts at the Cato Institute have already suggested that courts may view this as an end-run around Congress’s role in regulating commerce. The administration is betting it can move fast enough to extract concessions before litigation grinds the policy to a halt.
What makes this particularly complicated is the global nature of drug supply chains. A single medication might have active ingredients sourced from China, formulated in Ireland, and packaged in Puerto Rico before landing in an American pharmacy. Tariffs don’t neatly segregate those layers. They create bottlenecks, regulatory confusion, and opportunities for shortages. The Food and Drug Administration has warned repeatedly about vulnerabilities in the drug supply, but tariffs aren’t the fix they had in mind. The agency has been pushing for better transparency and redundancy in sourcing, not blunt economic instruments that could backfire during the next public health emergency.
There’s a human cost buried in these policy maneuvers. Patients with chronic conditions—diabetes, heart disease, autoimmune disorders—are watching this unfold with nervous attention. Advocacy groups like the Diabetes Patient Advocacy Coalition have been fielding calls from members worried about insulin prices spiking if manufacturers face new costs. The administration insists the opposite will happen, that drug prices will fall as companies compete to avoid tariffs by lowering costs. But that assumes a level of market rationality that doesn’t always exist in pharmaceuticals, where patents, exclusivity periods, and monopolistic practices dominate pricing more than competition does.
Politically, Trump is gambling that voters will credit him with taking on Big Pharma, an industry with approval ratings hovering near tobacco companies. Prescription drug costs remain one of the few issues with true bipartisan anger among the public. Republicans and Democrats alike want relief at the pharmacy counter. But the policy mechanism matters. If tariffs lead to shortages or price hikes, the backlash won’t care about intentions. It will land squarely on the administration that disrupted a fragile supply chain in the name of leverage.
The deals already struck with major drugmakers suggest that this is as much theater as policy. Companies committed to nebulous promises about American jobs and “fair pricing” in exchange for tariff exemptions. There’s little enforcement mechanism to hold them accountable three years from now. By then, a different administration might be in place, or the political landscape might have shifted enough that those commitments quietly dissolve. The companies that haven’t signed are either holding out for better terms or genuinely unable to meet the White House’s demands without upending their business models.
What happens Thursday will set the tone. If the tariffs land hard and broadly, expect litigation and lobbying to intensify immediately. If they’re narrow with extensive exemptions, it signals the administration is more interested in headlines than enforcement. Either way, the pharmaceutical industry is learning what steel and aluminum producers learned years ago: trade policy under Trump is less about economics and more about who blinks first.
